SLS (SELLAS Life Sciences Group) 1-Year Sharpe Ratio: 1.75 (As of Jul. 08, 2026)


SLS SELLAS Life Sciences Group Inc SLS
25 GF Score
Price $12.57
! 1 Warning Sign
View Full Analysis

What is SELLAS Life Sciences Group 1-Year Sharpe Ratio?

SELLAS Life Sciences Group SLS -6.93% 25 1-Year Sharpe Ratio is 1.75 as of Jul. 08, 2026. GuruFocus rates SLS with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-08), SELLAS Life Sciences Group's 1-Year Sharpe Ratio is 1.75.

SELLAS Life Sciences Group  (NAS:SLS) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

SELLAS Life Sciences Group 1-Year Sharpe Ratio Related Terms

SLS vs MBX, BHVN, PHVS: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, SELLAS Life Sciences Group's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SELLAS Life Sciences Group 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's 1-Year Sharpe Ratio falls into.


SLS
25GF Score
SELLAS Life Sciences Group Inc SLS
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SELLAS Life Sciences Group 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 1.75 mean?
SELLAS Life Sciences Group (SLS) has a 1-Year Sharpe Ratio of 1.75 as of Jul. 08, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for SELLAS Life Sciences Group and its competitors.
Is SELLAS Life Sciences Group's 1-Year Sharpe Ratio too high?
SELLAS Life Sciences Group's current 1-Year Sharpe Ratio is 1.75. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's 1-Year Sharpe Ratio compare to MBX and BHVN?
SELLAS Life Sciences Group's 1-Year Sharpe Ratio of 1.75 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for SELLAS Life Sciences Group and its competitors. SELLAS Life Sciences Group's current 1-Year Sharpe Ratio is 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current 1-Year Sharpe Ratio of 1.75. The current 1-Year Sharpe Ratio is 1.75. SELLAS Life Sciences Group's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current 1-Year Sharpe Ratio is 1.75 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SELLAS Life Sciences Group Business Description

Other Exchanges RXK3:Germany
Address 7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score

Get the complete analysis for SLS

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.57
Price